Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.
about
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsPlace of mTOR inhibitors in management of BKV infection after kidney transplantationDo wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsA systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipientsEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateEverolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the ratThe future direction and unmet needs of transplant immunosuppression.Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.The pros and the cons of mTOR inhibitors in kidney transplantation.Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation.A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant RecipientsLong-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimusMinimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation: Experience of one center.Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful.Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month resultsSafety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis.BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12.Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity study.Surgical wound complications after heart transplantation.The emerging role of Brazil in clinical trial conduct for transplantation.Everolimus: preventing organ rejection in adult kidney transplant recipients.Proteinuria after kidney transplantation.A drug safety evaluation of everolimus in kidney transplantation.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Is it time to give up with calcineurin inhibitors in kidney transplantation?Evolving perspectives of mTOR complexes in immunity and transplantation.Everolimus and sirolimus in transplantation-related but different.The safety of calcineurin inhibitors for kidney-transplant patients.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.The "ABC" of Virus-Specific T Cell Immunity in Solid Organ Transplantation.CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Variability in the reporting of renal function endpoints in immunosuppression trials in renal transplantation: time for consensus?
P2860
Q26749011-91D34718-ADB5-4EDF-9480-FBF52FAF1D9FQ26751556-E45495F5-59D7-45B0-A7B3-356B70B8BDDCQ26823281-204AEE5B-03C3-4B2E-A25A-0C8545047890Q27000107-31EA47A1-F951-4DCC-84CB-207EF66D146AQ28067598-3C72C933-D67A-487C-A98B-A916D50A29E5Q28484671-2B0AC2E3-2914-468E-85D4-63443A1D1FD7Q30277037-5D6AFCB1-E3FD-429E-8283-FFB49A50BDF5Q31138722-D8734660-DC70-4F15-9D04-1E8EEFD08FCCQ33412367-F63D6300-2CD3-4212-8175-0AB9C9ACDE24Q34289498-62017E14-9BB5-426E-BC5C-548296FF7F0FQ34805919-032A00EB-8B99-44DC-8347-FB2A9805F108Q35788609-4038897C-3CB4-40FE-9428-D5F6C8202490Q35827268-FB91BFB8-9309-46AC-A9A9-F6AE9A50B2A8Q36087779-BC55C13C-4322-4EAD-964D-3CEC50FE0AB1Q36250754-9067DB9D-FFAC-43DC-8396-37579F63CCC2Q36400872-D441D2C4-8965-4B2C-BA1B-A3A16331022AQ36400877-D16DD81B-8AF0-4806-88E4-9C65839248ACQ37033275-BA4E1D4C-D0FF-44B0-B743-BD228356450CQ37280007-9856B774-90B8-4411-98E3-A9E2E6114D9EQ37340200-C4A0D03B-AE19-41B0-AF49-D47C3E513508Q37464878-10E3043D-9AF3-494B-825A-BD2353BF5C8CQ37651129-E87009BA-F4EC-4F37-84B0-9223D0B850BEQ37854845-C4988A77-D17F-430C-940B-9516DBCA4F19Q37888772-16EDC5A3-E9C0-4A0F-83BB-DFE6DEE86F42Q37992135-B8164A01-C45B-42C6-9D73-3101DD1A7376Q38012182-5B2D31C4-9E2D-41BC-B47E-787EECF9C282Q38041260-4815AEEB-4903-4435-A3C4-B20867C13E5DQ38061056-5D2A55D4-A0EB-4174-8290-9A0D0745CB79Q38156847-3C174EC5-1870-46D4-84B2-636CF22D7BDAQ38367426-CFEBCEAC-67A1-4E28-8A45-094CC4BFDF0BQ38442560-84E0CD51-4637-4FFF-AF33-5499587AFF52Q38578386-6671CA1F-9723-4A16-A26A-E98864BDF2E1Q38668601-BB6079D4-56AB-4B21-9CBE-9397F6E51824Q38677902-87496427-05BC-4C13-A574-CE6439EC36FEQ38747503-B4140801-AF77-49D9-920D-2A0CEF4D43FBQ38818479-4DD67D28-1AF5-41BF-86C8-F0FBB8744B7BQ38839083-50A334DE-FB23-4B87-9891-F7E9F6181B63Q38947867-AA8C1AD8-2AF2-4C20-80FF-BFBC091870D4Q38962103-F7DD8E06-D194-4E32-B505-633F2C0A8571Q39291973-342BCD25-C176-48E4-BDBD-4A04A1581689
P2860
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Everolimus plus reduced-exposu ...... n renal-transplant recipients.
@en
Everolimus plus reduced-exposu ...... n renal-transplant recipients.
@nl
type
label
Everolimus plus reduced-exposu ...... n renal-transplant recipients.
@en
Everolimus plus reduced-exposu ...... n renal-transplant recipients.
@nl
prefLabel
Everolimus plus reduced-exposu ...... n renal-transplant recipients.
@en
Everolimus plus reduced-exposu ...... n renal-transplant recipients.
@nl
P2093
P1476
Everolimus plus reduced-exposu ...... in renal-transplant recipients
@en
P2093
H Tedesco Silva
T Johnston
P304
P356
10.1111/J.1600-6143.2010.03129.X
P407
P577
2010-04-28T00:00:00Z